Uncategorized
Intraocular anti-VEGF benefits patients with macular edema secondary to CRVO
Patients with macular edema secondary to central retinal vein occlusion experienced improved visual acuity and significantly reduced macular edema after intraocular injections of bevacizumab every 6 weeks for 12 months, a study found. The 12-month prospective analysis was composed of a 6-month randomized sham injection-controlled, double-masked clinical trial and a 6-month open-label extension.